A | FOR EVERY TRIAL, you must first define the characteristics and needs of the targeted patient population. Understanding the “voice of the patient” across diseases is critical, and groups are utilizing patient registries and qualitative methods to tackle this. I recently moderated a panel on chronic disease at the Aspen Spotlight Health and was also reminded of how critical it is to examine social determinants of health as we design trials. Human-centered design is critical to connecting the science of patient input into trials that are actually accessible for real people. We are at the dawn of how these new perspectives will alter how we design R&D practices.
MARGARET ANDERSON is a managing director at Deloitte. She was previously executive director at FasterCures, a center of the Milken Institute, and has extensive experience in biomedical policy with a focus on the patient.